New Oral SERD Elacestrant -- for Which Breast Cancer Patients? New Oral SERD Elacestrant -- for Which Breast Cancer Patients?
New data from the pivotal trial elacestrant in patients with ER+/HER2- metastatic breast cancer show subgroups that get the greatest progression-free survival benefit.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 14, 2022 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
T-DXd:'Remarkable' Survival Gains in Advanced Breast Cancer T-DXd:'Remarkable' Survival Gains in Advanced Breast Cancer
The antibody-drug conjugate trastuzumab deruxtecan continues to show impressive progression-free and overall survival gains in previously treated unresectable and/or metastatic HER2+ breast cancer.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 14, 2022 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Chemotherapy Meets Its Match Against Aggressive ER+/HER2 – BRCAs Chemotherapy Meets Its Match Against Aggressive ER+/HER2 – BRCAs
In the phase 2 RIGHT Choice study, first-line ribociclib, combined with either letrozole or anastrozole plus goserelin, was associated with a doubling of progression-free survival.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 13, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
CTC-guided Therapy Beats Physician Choice in Met Breast Cancer CTC-guided Therapy Beats Physician Choice in Met Breast Cancer
Better survival was seen when treatment choice between chemotherapy and endocrine therapy in women with HR+/HER2- metastatic breast cancer was guided by circulating tumor cell (CTC) counts.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 13, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
High Response Rates With T-DXd in Early HER2-Low Breast Cancer High Response Rates With T-DXd in Early HER2-Low Breast Cancer
"The study provides a rich platform for additional translational research to evaluate more sensitive methods of HER2 detection."MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 13, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
SABCS: Updated Analysis Confirms Endocrine Therapy Effective With/Without Chemo
Findings seen among HR - positive, HER2 - negative, node - negative early breast cancer patients with recurrence score of 11 to 25 (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 12, 2022 Category: Cancer & Oncology Tags: Gynecology, Oncology, Pharmacy, Conference News, Source Type: news
SABCS: Updated Analysis Confirms Endocrine Therapy Effective With/Without Chemo
MONDAY, Dec. 12, 2022 -- For patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-negative early breast cancer (EBC) with a 21-gene recurrence score (RS) of 11 to 25, adjuvant endocrine therapy... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 12, 2022 Category: Pharmaceuticals Source Type: news
Worse Breast Cancer Outcomes for Black Women Tempered by BMI Worse Breast Cancer Outcomes for Black Women Tempered by BMI
New data show that Black women with node positive HR+/HER2- breast cancer have worse outcomes than their white counterparts, although the difference was no longer significant after adjustment for BMI.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 8, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Dantari Debuts with $47 Million Series A to Advance Best-in-Class Targeted Medicines for Solid Tumors
Series A financing led by Westlake Village BioPartners with participation from Corner Ventures, Alexandria Venture Investments, and Caltech
Phase 1 data on lead product candidate in metastatic HER2-negative breast cancer, to be presented at San Antoni... Biopharmaceuticals, Oncology, Venture Capital Dantari , antibody-drug conjugate, Targeted High-capacity Drug Conjugate (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 8, 2022 Category: Pharmaceuticals Source Type: news
Phase III results show Roche's subcutaneous formulation of Tecentriq is comparable to intravenous Tecentriq and delivered in minutes
Administered under the skin, the subcutaneous formulation reduces time spent receiving treatment to approx. seven minutes, compared with 30-60 minutes for IV infusion1Roche has submitted data from the IMscin001 study to health authorities, seeking approval for the subcutaneous option across all approved indications of IVTecentriq If approved,Tecentriq would be Roche ’s fourth subcutaneous cancer therapy,2-4 helping to improve the treatment experience for patients. In addition, it could save resources for healthcare systems5-10Basel, 1 December 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new pivotal data ...
Source: Roche Investor Update - December 1, 2022 Category: Pharmaceuticals Source Type: news
FDA Rejects Piziotinib for Certain Types of NSCLC FDA Rejects Piziotinib for Certain Types of NSCLC
The drug was not approved for the treatment of patients with previously treated locally advanced or metastatic nonsmall cell lung cancer harboring HER2 exon 20 insertion mutations.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 25, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
FDA Rejects Poziotinib for Certain Types of NSCLC FDA Rejects Poziotinib for Certain Types of NSCLC
The drug was not approved for the treatment of patients with previously treated locally advanced or metastatic nonsmall cell lung cancer harboring HER2 exon 20 insertion mutations.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 25, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
Important Things to Consider With Early Stage
An expert discusses considerations for HER2-positive breast cancer care, including types of therapy, costs, side effects, and clinical trials. (Source: WebMD Health)
Source: WebMD Health - November 21, 2022 Category: Consumer Health News Source Type: news
Help Others Understand Your Diagnosis
Learn how to share news of your HER2-positive breast cancer diagnosis with family, friends, and others and get the support you need on your own terms. (Source: WebMD Health)
Source: WebMD Health - November 21, 2022 Category: Consumer Health News Source Type: news
What Role Now for Margetuximab in HER2 Breast Cancer? What Role Now for Margetuximab in HER2 Breast Cancer?
In the final report of a phase 3 trial, there was no overall survival advantage with margetuximab vs trastuzumab.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 14, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
